{"doi":"10.3390/cells12192369","title":"MicroRNA-30d-5p—A Potential New Therapeutic Target for Prevention of Ischemic Cardiomyopathy after Myocardial Infarction","abstract":"(1) Background and Objective: MicroRNAs (miRs) are biomarkers for assessing the extent of cardiac remodeling after myocardial infarction (MI) and important predictors of clinical outcome in heart failure. Overexpression of miR-30d-5p appears to have a cardioprotective effect. The aim of the present study was to demonstrate whether miR-30d-5p could be used as a potential therapeutic target to improve post-MI adverse remodeling. (2) Methods and Results: MiR profiling was performed by next-generation sequencing to assess different expression patterns in ischemic vs. healthy myocardium in a rat model of MI. MiR-30d-5p was significantly downregulated (p < 0.001) in ischemic myocardium and was selected as a promising target. A mimic of miR-30d-5p was administered in the treatment group, whereas the control group received non-functional, scrambled siRNA. To measure the effect of miR-30d-5p on infarct area size of the left ventricle, the rats were randomized and treated with miR-30d-5p or scrambled siRNA. Histological planimetry was performed 72 h and 6 weeks after induction of MI. Infarct area was significantly reduced at 72 h and at 6 weeks by using miR-30d-5p (72 h: 22.89 ± 7.66% vs. 35.96 ± 9.27%, p = 0.0136; 6 weeks: 6.93 ± 4.58% vs. 12.48 ± 7.09%, p = 0.0172). To gain insight into infarct healing, scratch assays were used to obtain information on cell migration in human umbilical vein endothelial cells (HUVECs). Gap closure was significantly faster in the mimic-treated cells 20 h post-scratching (12.4% more than the scrambled control after 20 h; p = 0.013). To analyze the anti-apoptotic quality of miR-30d-5p, the ratio between phosphorylated p53 and total p53 was evaluated in human cardiomyocytes using ELISA. Under the influence of the miR-30d-5p mimic, cardiomyocytes demonstrated a decreased pp53/total p53 ratio (0.66 ± 0.08 vs. 0.81 ± 0.17), showing a distinct tendency (p = 0.055) to decrease the apoptosis rate compared to the control group. (3) Conclusion: Using a mimic of miR-30d-5p underlines the cardioprotective effect of miR-30d-5p in MI and could reduce the risk for development of ischemic cardiomyopathy.","journal":"Cells","year":2023,"id":330519,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9613,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1054276,"name":"Vera Paar","orcid":"0000-0002-4743-3220","position":1,"is_corresponding":false},{"id":1054277,"name":"Bernhard Wernly","orcid":"0000-0003-4024-0220","position":2,"is_corresponding":false},{"id":1054278,"name":"Attila Kiss","orcid":"0000-0003-4652-1998","position":3,"is_corresponding":false},{"id":1054279,"name":"Moritz Mirna","orcid":"0000-0001-5679-4872","position":4,"is_corresponding":false},{"id":166246,"name":"Achim Aigner","orcid":"0000-0002-2778-6256","position":5,"is_corresponding":false},{"id":1054280,"name":"Eylem Acar","orcid":"0000-0002-0599-6893","position":6,"is_corresponding":false},{"id":1054733,"name":"Simon Watzinger","orcid":null,"position":7,"is_corresponding":false},{"id":1034552,"name":"Bruno K. Podesser","orcid":"0000-0002-4641-7202","position":8,"is_corresponding":false},{"id":1054281,"name":"Roland Zauner","orcid":"0000-0003-0590-3877","position":9,"is_corresponding":false},{"id":1054282,"name":"Verena Wally","orcid":"0000-0001-8705-3890","position":10,"is_corresponding":false},{"id":1054283,"name":"Michael Ablinger","orcid":"0000-0002-2001-4886","position":11,"is_corresponding":false},{"id":1054284,"name":"Matthias Hackl","orcid":"0000-0002-4136-7293","position":12,"is_corresponding":false},{"id":1054285,"name":"Uta C. Hoppe","orcid":"0000-0003-3632-4616","position":13,"is_corresponding":false},{"id":1054286,"name":"Michael Lichtenauer","orcid":"0000-0001-8403-3931","position":14,"is_corresponding":false},{"id":1054275,"name":"Elke Boxhammer","orcid":"0000-0002-6589-3853","position":0,"is_corresponding":true}],"reference_count":68,"raw_metadata":null,"created_at":"2026-07-19T01:09:10.120703Z","pmid":"37830583","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}